Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-01-07 00:00:00 ET · period of report 2022-01-05 · accession 0001714899-22-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-01-07 | 2022-01-05 | DNLI | Ho Carole | Chief Medical Off | S - Sale | $44.78 | -2,845 | 163.3K | -2% | -$127.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-05 | S | D | 2,845 | $44.78 | 163,285 | I See footnote | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.5101 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7500 restricted stock units held by the Reporting Person. (F4) The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |